Includes CDC recommendations for diagnosis and management of Shigella strains with possible reduced susceptibility to ciprofloxacin.
Shigella causes an estimated 500,000 cases of diarrhea in the U.S. each year.
Due to emerging resistance genes, some Shigella infections may be harder to treat with ciprofloxacin, an antibiotic that’s often a first choice when treatment is needed.
Treating Shigella infections with ciprofloxacin when resistance genes are present raises two concerns:
- The patient may have prolonged diarrhea or worsening of other symptoms, increased need for hospitalization, or a longer hospital stay.
- If the patient isn’t treated appropriately they could be contagious longer and may be more likely to spread the infection to other people.
Antimicrobial susceptibility tests (lab tests used to guide antibiotic choice) may not accurately predict whether Shigella infections with resistance genes can be treated effectively with ciprofloxacin.
If antibiotics are needed to treat a Shigella infection, it’s important to use one that will be effective. Using an antibiotic that isn’t effective can contribute to the growing problem of multidrug-resistant Shigella and increase the chance of others getting sick from this highly contagious germ. Read the full CDC Health Advisory for recommendations for clinicians, laboratories, and public health officials.
CDC is working with state and local public health departments and clinical partners to learn more about these new shigellosis cases and resistance genes.